Susan Bell, RN, MS, CNRN, APRN is currently working as a Program Clinical Lead at Candel Therapeutics, Inc., a biotechnology company that develops proprietary immuno-oncology platforms (Gene Mediated Cytotoxic Immunotherapy [GMCI™] and rQNestin34. 5) for the treatment of solid tumors, including brain. Prior to that, Sue worked for over 35 years at The Ohio State University Wexner Medical Center as an Acute Care Nurse Practitioner in Neurosurgery and Neuro-oncology. She served as the clinical research coordinator for multiple brain tumor studies including work in the Blood Brain Barrier Program. Sue holds an adjunct faculty position at The Ohio State College of Nursing and has served on multiple committees within the American Association of Neuroscience Nursing (AANN). She was content author for the clinical practice guideline series: Care of the Adult Patient with a Brain Tumor published by AANN. She served as the Society of Neuro-Oncology Education Day Co-chair and an ad hoc member on the Neuro-oncology Patient Survivorship Care Plan committee that published, “Survivorship Care Planning in Neuro-oncology” in Neuro-Oncology Practice. She is also the current Allied Health Representative of the Society for Neuro-oncology.